Spots Global Cancer Trial Database for Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
Official Title: Real-world Experience of Anti-PD-1 Immunotherapy Plus Chemotherapy as First-line Treatment for Patients With Advanced Oesophageal Squamous Cell Carcinoma in China(REACTION Trial).
Study ID: NCT05142709
Interventions
Study Description
Brief Summary: This study is a multi-center, non-interventional study. Clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (ESCC) patients.
Detailed Description: This study is a multi-center, non-interventional study. Patients' background, treatment pattern, treatment outcome, efficacy will be collected in metastatic esophageal squamous cell carcinoma (ESCC) patients who were treated with ICIs as 1st line treatment at approximately 26 institutions. The patients should have received at least 1 cycle of anti-PD-1 immunotherapy with or without radiotherapy. Based on these data, overall survival (OS), progression free survival (PFS) from start of 1st line treatment and the role and efficacy of radiotherapy for these patients will be assessed.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The 2nd affiliated hospital of Bengbu medical University, Bengbu, Anhui, China
The 2nd people's hospital of Anhui province, Hefei, Anhui, China
Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China
The 1st affiliated hospital of Xiamen University, Xiamen, Fujian, China
Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center, Shenzhen, Guangdong, China
The 4th affiliated hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Anyang cancer hospital, Anyang, Henan, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Wuhan University Zhongnan hospital, Wuhan, Hubei, China
Zhongnan University Xiangya Hospital, Changsha, Hunan, China
Huai'an first hospital, Huai'an, Jiangsu, China
Jiangsu cancer Hosipital, Nanjing, Jiangsu, China
Nantong cancer hospital, Nantong, Jiangsu, China
Yancheng the 3rd hospital, Yancheng, Jiangsu, China
The Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China
Jiangxi Cancer Hospital, Nanchang, Jiangxi, China
The 1st affiliated hospital of Nanchang University, Nanchang, Jiangxi, China
The 2nd affiliated hospital of Nanchang University, Nanchang, Jiangxi, China
The First Affiliated Hospital of Air Force Medical University, Xi'an, Shaanxi, China
Fudan University Shanghai cancer center, Shanghai, Shanghai, China
Sichuan cancer hospital, Chengdu, Sichuan, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
The 2nd affiliated hospital of Wenzhou medical university, Wenzhou, Zhejiang, China
Contact Details
Name: Lvhua Wang, M.D.
Affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Role: PRINCIPAL_INVESTIGATOR
Name: Kuaile Zhao, M.D.
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
